Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis



Status:Completed
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - 90
Updated:9/7/2018
Start Date:October 2015
End Date:August 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The purpose of this research study to find out if a drug called OctreoScan or DOTATATE can
help doctors diagnose people with cardiac sarcoidosis better.

OctreoScan and DOTATATE are both approved by the U.S. Food and Drug Administration (FDA) to
diagnose certain tumors.


Inclusion Criteria:

- Individuals aged 18 or older

- Documentation of biopsy-proven sarcoidosis OR patients with typical findings on FDG
PET and MRI without previous biopsy

- Clinical suspicion of cardiac involvement defined as the presence of any of the
following: high-degree A-V nodal block, complete bundle branch block, reduced left or
right ventricular systolic function, any cardiac arrhythmia, and/or unexplained chest
pain, dyspnea or syncope

- PET/CT imaging demonstrating abnormal myocardial FDG uptake consistent with active
inflammatory myocardium.

Exclusion Criteria:

- Initiation of steroids or any other immunosuppressive medication(s) following the
completion of FDG-PET, as these medications, in theory, may subsequently suppress
OctreoScan or DOTATATE uptake in the heart.

- Patients with history of neuroendocrine tumors (specially insulinomas)

- Patients taking the medication Octreotide

- Patients on total parenteral nutrition (TPN)

- Women who are pregnant or breastfeeding
We found this trial at
1
site
Brigham and Women's Hosp
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Phone: 617-525-8322
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials